| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Nathan A Gillespie, Kenneth S Kendle. Use of Genetically Informed Methods to Clarify the Nature of the Association Between Cannabis Use and Risk for Schizophrenia. JAMA psychiatry. vol 78. issue 5. 2021-05-06. PMID:33146687. |
use of genetically informed methods to clarify the nature of the association between cannabis use and risk for schizophrenia. |
2021-05-06 |
2023-08-13 |
Not clear |
| Jane Pei-Chen Chang, Kuan-Pin S. Nutrition and immunology in mental health: Precision medicine and integrative approaches to address unmet clinical needs in psychiatric treatments. Brain, behavior, and immunity. vol 85. 2021-04-27. PMID:31568824. |
in this special issue, we included 15 papers discussing the role of nutrition (blueberries, omega-3 polyunsaturated fatty acids, melatonergic agonist, s-adenosyl-l-methionine, cannabidiol and kratom) in the context of immunoregulation across different psychiatric disorders from depression, bipolar disorders, and schizophrenia to alcohol-induced dementia and anorexia nervosa. |
2021-04-27 |
2023-08-13 |
Not clear |
| Naielly Rodrigues da Silva, Felipe Villela Gomes, Andreza Buzolin Sonego, Nicole Rodrigues da Silva, Francisco Silveira Guimarãe. Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors. Pharmacological research. vol 156. 2021-04-22. PMID:32151683. |
cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-ht1a, but not cb1 and cb2 receptors. |
2021-04-22 |
2023-08-13 |
mouse |
| Marta Barrera-Conde, Karina Ausin, Mercedes Lachén-Montes, Joaquín Fernández-Irigoyen, Liliana Galindo, Aida Cuenca-Royo, Cristina Fernández-Avilés, Víctor Pérez, Rafael de la Torre, Enrique Santamaría, Patricia Robled. Cannabis Use Induces Distinctive Proteomic Alterations in Olfactory Neuroepithelial Cells of Schizophrenia Patients. Journal of personalized medicine. vol 11. issue 3. 2021-04-13. PMID:33668817. |
cannabis use induces distinctive proteomic alterations in olfactory neuroepithelial cells of schizophrenia patients. |
2021-04-13 |
2023-08-13 |
human |
| Marta Barrera-Conde, Karina Ausin, Mercedes Lachén-Montes, Joaquín Fernández-Irigoyen, Liliana Galindo, Aida Cuenca-Royo, Cristina Fernández-Avilés, Víctor Pérez, Rafael de la Torre, Enrique Santamaría, Patricia Robled. Cannabis Use Induces Distinctive Proteomic Alterations in Olfactory Neuroepithelial Cells of Schizophrenia Patients. Journal of personalized medicine. vol 11. issue 3. 2021-04-13. PMID:33668817. |
a close epidemiological link has been reported between cannabis use and schizophrenia (scz). |
2021-04-13 |
2023-08-13 |
human |
| Michał Graczyk, Małgorzata Łukowicz, Tomasz Dzierzanowsk. Prospects for the Use of Cannabinoids in Psychiatric Disorders. Frontiers in psychiatry. vol 12. 2021-03-30. PMID:33776815. |
several studies have investigated the influence of potential genetic factors on psychosis and schizophrenia development after cannabis use. |
2021-03-30 |
2023-08-13 |
Not clear |
| Belen Arranz, Marina Garriga, Miquel Bernardo, Ana Gonzalez-Pinto, Manuel Arrojo, Marta Torrens, Judith Tirado-Muñoz, Francina Fonseca, Pilar A Saiz, Gerardo Florez, Jose Manuel Goikolea, Iñaki Zorrilla, Ruth Cunill, Xavi Castells, Elisardo Becoña, Ana Lopez, Luis Sa. Clinical Practice Guideline on Pharmacological and Psychological management of adult patients with Schizophrenia Spectrum Disorders and a comorbid substance use. Adicciones. vol 0. issue 0. 2021-03-26. PMID:33768260. |
our results suggest: 1) in patients with schizophrenia and cannabis use disorder, it is not possible to recommend one antipsychotic drug over another (between olanzapine, risperidone or haloperidol) for improving psychotic symptoms, reducing cannabis use, or improving pragmatic variables (weak recommendation). |
2021-03-26 |
2023-08-13 |
Not clear |
| Tao Yu, Tianye Jia, Liping Zhu, Sylvane Desrivières, Christine Macare, Yan Bi, Arun L W Bokde, Erin Burke Quinlan, Andreas Heinz, Bernd Ittermann, ChuanXin Liu, Lei Ji, Tobias Banaschewski, Decheng Ren, Li Du, Binyin Hou, Herta Flor, Vincent Frouin, Hugh Garavan, Penny Gowland, Jean-Luc Martinot, Marie-Laure Paillère Martinot, Frauke Nees, Dimitri Papadopoulos Orfanos, Qiang Luo, Congying Chu, Tomas Paus, Luise Poustka, Sarah Hohmann, Sabina Millenet, Michael N Smolka, Nora C Vetter, Eva Mennigen, Cai Lei, Henrik Walter, Juliane H Fröhner, Robert Whelan, Guang He, Lin He, Gunter Schumann, Gabriel Rober. Cannabis-Associated Psychotic-like Experiences Are Mediated by Developmental Changes in the Parahippocampal Gyrus. Journal of the American Academy of Child and Adolescent Psychiatry. vol 59. issue 5. 2021-03-18. PMID:31326579. |
cannabis consumption during adolescence has been reported as a risk factor for psychotic-like experiences (ples) and schizophrenia. |
2021-03-18 |
2023-08-13 |
Not clear |
| Sergi Saladrigas-Manjón, Tanja Dučić, Liliana Galindo, Cristina Fernández-Avilés, Víctor Pérez, Rafael de la Torre, Patricia Robled. Effects of Cannabis Use on the Protein and Lipid Profile of Olfactory Neuroepithelium Cells from Schizophrenia Patients Studied by Synchrotron-Based FTIR Spectroscopy. Biomolecules. vol 10. issue 2. 2021-03-15. PMID:32092878. |
effects of cannabis use on the protein and lipid profile of olfactory neuroepithelium cells from schizophrenia patients studied by synchrotron-based ftir spectroscopy. |
2021-03-15 |
2023-08-13 |
human |
| Behnaz Khavari, Murray J Cairn. Epigenomic Dysregulation in Schizophrenia: In Search of Disease Etiology and Biomarkers. Cells. vol 9. issue 8. 2021-03-10. PMID:32764320. |
while schizophrenia has a strong genetic component, with heritability around 80%, there is also a very significant range of environmental exposures and stressors that have been implicated in disease development and neuropathology, such as maternal immune infection, obstetric complications, childhood trauma and cannabis exposure. |
2021-03-10 |
2023-08-13 |
Not clear |
| Hannah J Jones, Gemma Hammerton, Tayla McCloud, Lindsey A Hines, Caroline Wright, Suzanne H Gage, Peter Holmans, Peter B Jones, George Davey Smith, David E J Linden, Michael C O'Donovan, Michael J Owen, James T Walters, Marcus R Munafò, Jon Heron, Stanley Zammi. Examining pathways between genetic liability for schizophrenia and patterns of tobacco and cannabis use in adolescence. Psychological medicine. 2021-03-04. PMID:32515721. |
examining pathways between genetic liability for schizophrenia and patterns of tobacco and cannabis use in adolescence. |
2021-03-04 |
2023-08-13 |
Not clear |
| Hannah J Jones, Gemma Hammerton, Tayla McCloud, Lindsey A Hines, Caroline Wright, Suzanne H Gage, Peter Holmans, Peter B Jones, George Davey Smith, David E J Linden, Michael C O'Donovan, Michael J Owen, James T Walters, Marcus R Munafò, Jon Heron, Stanley Zammi. Examining pathways between genetic liability for schizophrenia and patterns of tobacco and cannabis use in adolescence. Psychological medicine. 2021-03-04. PMID:32515721. |
we, therefore, examined whether schizophrenia genetic risk associates with longitudinal patterns of cigarette and cannabis use in adolescence and mediating pathways for any association to inform potential reduction strategies. |
2021-03-04 |
2023-08-13 |
Not clear |
| Cássio Morais Loss, Lucas Teodoro, Gabriela Doná Rodrigues, Lucas Roberto Moreira, Fernanda Fiel Peres, Antonio Waldo Zuardi, José Alexandre Crippa, Jaime Eduardo Cecilio Hallak, Vanessa Costhek Abíli. Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? Frontiers in pharmacology. vol 11. 2021-02-23. PMID:33613289. |
is cannabidiol during neurodevelopment a promising therapy for schizophrenia and autism spectrum disorders? |
2021-02-23 |
2023-08-13 |
Not clear |
| Mélissa Beaudoin, Stéphane Potvin, Charles-Edouard Giguère, Sophie-Lena Discepola, Alexandre Dumai. Persistent cannabis use as an independent risk factor for violent behaviors in patients with schizophrenia. NPJ schizophrenia. vol 6. issue 1. 2021-02-13. PMID:32393793. |
persistent cannabis use as an independent risk factor for violent behaviors in patients with schizophrenia. |
2021-02-13 |
2023-08-13 |
Not clear |
| Mélissa Beaudoin, Stéphane Potvin, Charles-Edouard Giguère, Sophie-Lena Discepola, Alexandre Dumai. Persistent cannabis use as an independent risk factor for violent behaviors in patients with schizophrenia. NPJ schizophrenia. vol 6. issue 1. 2021-02-13. PMID:32393793. |
although recent studies have shown a moderately strong association between cannabis use and violence among people with severe mental disorders, the direction of this association has not been investigated prospectively in a population with schizophrenia. |
2021-02-13 |
2023-08-13 |
Not clear |
| Mélissa Beaudoin, Stéphane Potvin, Charles-Edouard Giguère, Sophie-Lena Discepola, Alexandre Dumai. Persistent cannabis use as an independent risk factor for violent behaviors in patients with schizophrenia. NPJ schizophrenia. vol 6. issue 1. 2021-02-13. PMID:32393793. |
therefore, this study aims to determine, using cross-lag models, whether a temporal relationship between cumulative cannabis use and violence exists in a population with schizophrenia. |
2021-02-13 |
2023-08-13 |
Not clear |
| Joëlle A Pasman, Karin J H Verweij, Zachary Gerring, Sven Stringer, Sandra Sanchez-Roige, Jorien L Treur, Abdel Abdellaoui, Michel G Nivard, Bart M L Baselmans, Jue-Sheng Ong, Hill F Ip, Matthijs D van der Zee, Meike Bartels, Felix R Day, Pierre Fontanillas, Sarah L Elson, Harriet de Wit, Lea K Davis, James MacKillop, Jaime L Derringer, Susan J T Branje, Catharina A Hartman, Andrew C Heath, Pol A C van Lier, Pamela A F Madden, Reedik Mägi, Wim Meeus, Grant W Montgomery, A J Oldehinkel, Zdenka Pausova, Josep A Ramos-Quiroga, Tomas Paus, Marta Ribases, Jaakko Kaprio, Marco P M Boks, Jordana T Bell, Tim D Spector, Joel Gelernter, Dorret I Boomsma, Nicholas G Martin, Stuart MacGregor, John R B Perry, Abraham A Palmer, Danielle Posthuma, Marcus R Munafò, Nathan A Gillespie, Eske M Derks, Jacqueline M Vin. Author Correction: GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability. Nature neuroscience. vol 22. issue 7. 2021-02-03. PMID:31168101. |
author correction: gwas of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability. |
2021-02-03 |
2023-08-13 |
Not clear |
| Joëlle A Pasman, Karin J H Verweij, Zachary Gerring, Sven Stringer, Sandra Sanchez-Roige, Jorien L Treur, Abdel Abdellaoui, Michel G Nivard, Bart M L Baselmans, Jue-Sheng Ong, Hill F Ip, Matthijs D van der Zee, Meike Bartels, Felix R Day, Pierre Fontanillas, Sarah L Elson, Harriet de Wit, Lea K Davis, James MacKillop, Jaime L Derringer, Susan J T Branje, Catharina A Hartman, Andrew C Heath, Pol A C van Lier, Pamela A F Madden, Reedik Mägi, Wim Meeus, Grant W Montgomery, A J Oldehinkel, Zdenka Pausova, Josep A Ramos-Quiroga, Tomas Paus, Marta Ribases, Jaakko Kaprio, Marco P M Boks, Jordana T Bell, Tim D Spector, Joel Gelernter, Dorret I Boomsma, Nicholas G Martin, Stuart MacGregor, John R B Perry, Abraham A Palmer, Danielle Posthuma, Marcus R Munafò, Nathan A Gillespie, Eske M Derks, Jacqueline M Vin. Author Correction: GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability. Nature neuroscience. vol 22. issue 7. 2021-02-03. PMID:31168101. |
several occurrences of the word 'schizophrenia' have been re-worded as 'liability to schizophrenia' or 'schizophrenia risk', including in the title, which should have been "gwas of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability," as well as in supplementary figures 1-10 and supplementary tables 7-10, to more accurately reflect the findings of the work. |
2021-02-03 |
2023-08-13 |
Not clear |
| Julie Schoevers, Judith E Leweke, F Markus Lewek. Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies. Current opinion in psychiatry. vol 33. issue 3. 2021-02-01. PMID:32073423. |
cannabidiol as a treatment option for schizophrenia: recent evidence and current studies. |
2021-02-01 |
2023-08-13 |
Not clear |
| Julie Schoevers, Judith E Leweke, F Markus Lewek. Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies. Current opinion in psychiatry. vol 33. issue 3. 2021-02-01. PMID:32073423. |
the most recent studies published or initiated in the last 18 months, investigating cannabidiol in the treatment of symptoms of schizophrenia and related conditions are summarized, including observed tolerability and reported side-effects. |
2021-02-01 |
2023-08-13 |
Not clear |